{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:26Z","timestamp":1783401326610,"version":"3.54.6"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08194-9","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:54:42Z","timestamp":1780538082000},"page":"4083-4089","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term effectiveness and safety of annual biosimilar Rituximab retreatment in seropositive Rheumatoid Arthritis: A 4-year real-world study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2414-6082","authenticated-orcid":false,"given":"Syamasis","family":"Bandyopadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-9644","authenticated-orcid":false,"given":"Aheli Ghosh","family":"Dastidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7926-1897","authenticated-orcid":false,"given":"Subhendu Datta","family":"Bhowmik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8427-3203","authenticated-orcid":false,"given":"Sandip Kumar","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6716-2641","authenticated-orcid":false,"given":"Aloke","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avishek","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"3","key":"8194_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/BOR.0b013e3283369cb8","volume":"22","author":"B Marston","year":"2010","unstructured":"Marston B, Palanichamy A, Anolik JH (2010) B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol 22(3):307\u201315. https:\/\/doi.org\/10.1097\/BOR.0b013e3283369cb8","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"8194_CR2","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.131279","volume":"41","author":"F De Keyser","year":"2014","unstructured":"De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R, MIRA Study Group (2014) Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. J Rheumatol 41(9):1761\u20135. https:\/\/doi.org\/10.3899\/jrheum.131279","journal-title":"J Rheumatol"},{"issue":"5","key":"8194_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3899\/jrheum.111488","volume":"40","author":"A V\u00e1ncsa","year":"2013","unstructured":"V\u00e1ncsa A, Szab\u00f3 Z, Szamosi S, Bodn\u00e1r N, V\u00e9gh E, Gergely L, Szucs G, Sz\u00e1nt\u00f3 S, Szekanecz Z (2013) Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion. J Rheumatol 40(5):565\u2013571. https:\/\/doi.org\/10.3899\/jrheum.111488","journal-title":"J Rheumatol"},{"key":"8194_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/ard.2010.137703","volume":"70","author":"PP Tak","year":"2011","unstructured":"Tak PP, Rigby WF, Rubbert-Roth A et al (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70:39\u201346","journal-title":"Ann Rheum Dis"},{"key":"8194_CR5","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8812.1","volume":"5","author":"DL Scott","year":"2016","unstructured":"Scott DL (2016) Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments. F1000Res 5:F1000","journal-title":"F1000Res"},{"key":"8194_CR6","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","volume":"75","author":"T D\u00f6rner","year":"2016","unstructured":"D\u00f6rner T, Strand V, Cornes P et al (2016) The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 75:974\u2013982","journal-title":"Ann Rheum Dis"},{"key":"8194_CR7","first-page":"3762","volume":"8","author":"M Greenwald","year":"2018","unstructured":"Greenwald M, Tesser J, Sewell KL (2018) Biosimilars have arrived: rituximab. Arthritis 8:3762\u20133864","journal-title":"Arthritis"},{"key":"8194_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/14712598.2019.1665018","volume":"19","author":"JY Jung","year":"2019","unstructured":"Jung JY, Kim JW, Kim HA et al (2019) Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 19:979\u2013986","journal-title":"Expert Opin Biol Ther"},{"key":"8194_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4103\/AJIM.AJIM_30_19","volume":"7","author":"R Subramanian","year":"2019","unstructured":"Subramanian R, Prasad S (2019) Biologics: a tectonic shift in the management of rheumatoid arthritis. APIK J Intern Med 7:103\u2013108","journal-title":"APIK J Intern Med"},{"key":"8194_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40259-019-00376-z","volume":"33","author":"S Lee","year":"2019","unstructured":"Lee S, Lee H, Kim E (2019) Comparative efficacy and safety of biosimilar rituximab and originator rituximab in rheumatoid arthritis and Non-Hodgkin\u2019s Lymphoma: a systematic review and meta-analysis. BioDrugs 33:469\u2013483","journal-title":"BioDrugs"},{"key":"8194_CR11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4103\/ijmpo.ijmpo_25_17","volume":"39","author":"A Suresh","year":"2018","unstructured":"Suresh A, Ghanashyam B, Sinha S et al (2018) A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (rituximab, Roche) in Indian patients of Non-Hodgkin\u2019s lymphoma (HERILY). Indian J Med Paediatr Oncol 39:316\u2013320","journal-title":"Indian J Med Paediatr Oncol"},{"key":"8194_CR12","unstructured":"Manjeet Bhati, Syamasis Bandyopadhyay; Efficacy and safety of an anti-CD20 monoclonal antibody (RedituxRA\u2122) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs."},{"issue":"10","key":"8194_CR13","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF Van Vollenhoven","year":"2015","unstructured":"Van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB (2015) Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 42(10):1761\u20136. https:\/\/doi.org\/10.3899\/jrheum.150051","journal-title":"J Rheumatol"},{"issue":"10","key":"8194_CR14","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF van Vollenhoven","year":"2015","unstructured":"van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB (2015) Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 42(10):1761\u20131766","journal-title":"J Rheumatol"},{"key":"8194_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-025-00530-x","volume":"9","author":"D Bertrand","year":"2025","unstructured":"Bertrand D, De Meyst E, Doumen M et al (2025) Effectiveness and patient-reported impact of on-flare retreatment in patients with rheumatoid arthritis: insights from retrospective long-term real-world data. BMC Rheumatol 9:91","journal-title":"BMC Rheumatol"},{"issue":"12","key":"8194_CR16","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s00296-023-05524-x","volume":"44","author":"L Schapink","year":"2024","unstructured":"Schapink L, den Broeder N, den Broeder AA, Verhoef LM (2024) Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort study. Rheumatol Int 44(12):2921\u20132925. https:\/\/doi.org\/10.1007\/s00296-023-05524-x","journal-title":"Rheumatol Int"},{"key":"8194_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-eular.2051","volume":"71","author":"K Chatzidionysiou","year":"2012","unstructured":"Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, Ancuta I, Pavelka K, Nordstr\u00f6m D, Gabay C, Canhao H, Tomsic M, Van Riel P, Gomez-Reino J, Kvien T, Van Vollenhoven R (2012) THU0086\u2005Seropositivity and response to RTX: data from the Cererra collaboration. Ann Rheum Dis 71:182. https:\/\/doi.org\/10.1136\/annrheumdis-2012-eular.2051","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"8194_CR18","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1093\/rheumatology\/kez152","volume":"58","author":"SC Shim","year":"2019","unstructured":"Shim SC, Bo\u017ei\u0107-Majstorovi\u0107 L, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Cons Molina FF, Medina-Rodriguez FG, Miranda P, Shesternya P, Chavez-Corrales J, Wiland P, Jeka S, Garmish O, Hrycaj P, Fomina N, Park W, Suh CH, Lee SJ, Lee SY, Bae YJ, Yoo DH (2019Dec 1) Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. Rheumatology (Oxford) 58(12):2193\u20132202","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"8194_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/rheumatology\/keaa234","volume":"60","author":"JS Smolen","year":"2021","unstructured":"Smolen JS, Cohen SB, Tony HP, Scheinberg M, Kivitz A, Balanescu A, Gomez-Reino J, Cen L, Poetzl J, Shisha T, Kollins D (2021Jan 5) Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. Rheumatology (Oxford) 60(1):256\u2013262","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"8194_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13075-024-03456-w","volume":"26","author":"N Maharaj","year":"2024","unstructured":"Maharaj N, Uppada DR, Reddy N, Reddy P, Batalov A, Lvanova D, Staykova N, Baranauskaite A, Hassan LA (2024Dec 21) Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study. Arthritis Res Ther 26(1):225","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08194-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08194-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08194-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:28:05Z","timestamp":1783398485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08194-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8194"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08194-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was taken from the Institutional Ethical Committee, Apollo Multispeciality Hospitals Kolkata (Study reference number\u00a0IEC\/BR\/2025\/11\/40)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval"}},{"value":"Waiver of informed consent was granted by the institutional ethical committee as it was a retrospective study dealing with anonymous data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}